NCT01932528

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: Male
• Age: 30 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.

Conditions

• Carcinoid Syndrome

Interventions

Type	Name	Description
DRUG	500 mg [14C]-LX1606	500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.

Timeline

• Start date: 2013-08-01
• Primary completion: 2013-09-01
• First posted: 2013-08-30
• Last updated: 2013-10-23

Locations

1 site across 1 country: United Kingdom